Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation

SIMPLE SUMMARY: Previous studies of first-generation EGFR-TKI erlotinib and bevacizumab combination have demonstrated superior treatment efficacy compared to erlotinib monotherapy for advanced EGFR-mutant NSCLC patients. Whether this combination benefit can also be observed in second-generation EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Chih-Hsi Scott, Chiu, Tzu-Hsuan, Tung, Pi-Hung, Huang, Chi-Hsien, Ju, Jia-Shiuan, Huang, Allen Chung-Cheng, Wang, Chin-Chou, Ko, Ho-Wen, Hsu, Ping-Chih, Fang, Yueh-Fu, Guo, Yi-Ke, Yang, Cheng-Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773866/
https://www.ncbi.nlm.nih.gov/pubmed/35053480
http://dx.doi.org/10.3390/cancers14020316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773866/
https://www.ncbi.nlm.nih.gov/pubmed/35053480
http://dx.doi.org/10.3390/cancers14020316

Ejemplares similares